Abstract:IntroductionSurvival after surgery of pancreatic cancer is still poor, even after curative resection. Some prognostic factors like the status of the resection margin, lymph node (LN) status, or tumor grading have been identified. However, only few data have been published regarding the prognostic influence of the LN ratio (number of LN involved to number of examined LN). We, therefore, evaluated potential prognostic factors in 182 patients after resection of pancreatic cancer including assessment of LN ratio.MethodsSince 1994, 204 patients underwent pancreatic resection for ductal pancreatic adenocarcinoma. Survival was evaluated in 182 patients with complete follow-up evaluations. Of those 182 patients, 88% had cancer of the pancreatic head, 5% of the body, and 7% of the pancreatic tail. Patients underwent pancreatoduodenectomy (85%), distal resection (12%), or total pancreatectomy (3%). Survival was analyzed by the Kaplan–Meier and Cox methods.ResultsIn all 204 resected patients, operative mortality was 3.9% (n = 8). In the 182 patients with follow-up, 70% had free resection margins, 62% had G1- or G2-classified tumors, and 70% positive LN. Median tumor size was 30 (7–80) mm. The median number of examined LN was 16 and median number of involved LN 1 (range 0–22). Median LN ratio was 0.1 (0–0.79). Cumulative 5-year survival (5-year SV) in all patients was 15%. In univariate analysis, a LN ratio ≥ 0.2 (5-year SV 6% vs. 19% with LN ratio < 0.2; p = 0.003), LN ratio ≥ 0.3 (5-year SV 0% vs. 18% with LN ratio < 0.3; p < 0.001), a positive resection margin (p < 0.01) and poor differentiation (G3/G4; p < 0.03) were associated with poorer survival. In multivariate analysis, a LN ratio ≥ 0.2 (p < 0.02; relative risk RR 1.6), LN ratio ≥ 0.3 (p < 0.001; RR 2.2), positive margins (p < 0.02; RR 1.7), and poor differentiation (p < 0.03; RR 1.5) were independent factors predicting a poorer outcome. The conventional nodal status or the number of examined nodes (in all patients and in the subgroups of node positive or negative patients) had no significant influence on survival. Patients with one metastatic LN had the same outcome as patients with negative nodes, but prognosis decreased significantly in patients with two or more LN involved.ConclusionsNot the lymph node involvement per se but especially the LN ratio is an independent prognostic factor after resection of pancreatic cancers. In our series, the LN ratio was even the strongest predictor of survival. The routine estimation of the LN ratio may be helpful not only for the individual prediction of prognosis but also for the indication of adjuvant therapy and herein related outcome and therapy studies.

Lymph Node Status Predicts the Benefit of Adjuvant Chemoradiotherapy for Patients with Resected Pancreatic Cancer.

Adjuvant Chemotherapy, with or Without Postoperative Radiotherapy, for Resectable Advanced Pancreatic Adenocarcinoma: Continue or Stop?

Reduced Lymph Node Harvest after Neoadjuvant Chemotherapy in Gastric Cancer.

The Value of Lymph Node Ratio in the Prediction of Rectal Cancer Patient Survival after Preoperative Chemoradiotherapy.

Effect of the Number of Positive Lymph Nodes and Lymph Node Ratio on Prognosis of Patients after Resection of Pancreatic Adenocarcinoma

Impact of Lymphadenectomy Extent on Immunotherapy Efficacy in Postresectional Recurred Non-Small Cell Lung Cancer: a Multi-Institutional Retrospective Cohort Study.

Postoperative Serum CA19-9, CEA and CA125 Predicts the Response to Adjuvant Chemoradiotherapy Following Radical Resection in Pancreatic Adenocarcinoma.

Resected Pancreatic Cancer with N2 Node Involvement is Refractory to Gemcitabine-Based Adjuvant Chemotherapy

Number of Positive Lymph Nodes is Superior to LNR and LODDS for Predicting the Prognosis of Pancreatic Neuroendocrine Neoplasms

The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer

Impact of Lymph Node Metastasis on Survival of Patients with Pancreatic Cancer

Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection margin, and receiving adjuvant chemotherapy

Efficacy of adjuvant chemoradiotherapy in patients with pancreatic ductal adenocarcinoma after surgery: A real-world study in high-volume pancreatic cancer center.

Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma

Chemoradiotherapy is Associated with Improved Survival for Resected Pancreatic Adenosquamous Carcinoma

Lymph Node Ratio-Based Model for Predicting Survival and Assessing the Benefit of Adjuvant Chemotherapy in Postoperative Duodenal Adenocarcinoma.

Log odds of positive lymph nodes is a robust predictor of survival and benefits from postoperative radiotherapy in stage IIIA-N2 resected non-small cell lung cancer

Lymph node ratio predicts prognosis in patients with surgically resected invasive pancreatic cystic neoplasms

Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study

Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi‐institutional analysis

Chemoradiotherapy is Associated with Improved Survival for Resected Pancreatic Adenosquamous Carcinoma: a Retrospective Cohort Study from the SEER Database